Drug Trial Radar · NCT02496663
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
May 11, 2016
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jul 14, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the safety, side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back after a period of improvement (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be safe, tolerable in treating patients with EGFR-mutant non-small cell lung cancer.
Conditions
- Metastatic Lung Non-Small Cell Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT scan
Echocardiography TestProcedure
Undergo ECHO
Magnetic Resonance ElastographyProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
NecitumumabBiological
Given IV
OsimertinibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) of necitumumab combined with osimertinibTime frame: 21 days
- Incidence of toxicityTime frame: Up to 1 year
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
UCHealth University of Colorado Hospital
Aurora, Colorado
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Emory University Hospital Midtown
Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Emory Saint Joseph's Hospital
Atlanta, Georgia
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Duke Cancer Center Cary
Cary, North Carolina
Duke University Medical Center
Durham, North Carolina
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.